Rocuronium for rapid sequence induction Presenters: Dr. Said Nawaz. Dr.Reem Al-safar. Dr.Ahmed Al-sharif. Dr.Abdulla Al-harbi.

Slides:



Advertisements
Similar presentations
PHARMACOKINETIC.
Advertisements

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 16 Drugs That Block Nicotinic Cholinergic Transmission: Neuromuscular Blocking.
Rapid Sequence Intubation Khalid Al-Ansari, FRCP(C), FAAP(PEM)
#5 Intro to EM Airway Management- RSI Pharmacology Andrew Brainard 1.
Selected Clinical Calculations
Rapid Sequence Intubation
Skeletal Muscle Relaxants (Neuromuscular Blocking Agents)
VECURONIUM BROMIDE Familiarization Training. General Information Vecuronium is a non-depolarizing neuromuscular blocking agent, preventing acetylcholine.
Prolonged Propofol Anesthesia Is Not Associated with an Increase in Blood Lactate Anesth Analg 2009;109:1105 – 10.
CLINICAL PHARMACOLOGY OF ROCURONIUM BROMIDE Jerrold H. Levy, MD Professor of Anesthesiology Emory University School of Medicine Division of Cardiothoracic.
The Dose Of Succinylcholine in Morbid Obesity By Harry Lemmens & Jay Brodsky Anesthesia Dep. In Sanford University School of Medicine,Sanford, Claifornia.
Skeletal muscle relaxants
Principles of Pharmacology. SOURCES AND NAMES OF DRUGS Sources of Drugs Many drugs are isolated from plants or chemically derived from plant substances.
Skeletal muscle relaxants
NEUROMUSCULAR JUNCTION BLOCKERS BY :DR ISRAA OMAR.
Procedural Sedation Pharmacology Deb Updegraff R.N., P.N.P, C.N.S. Clinical Nurse Specialist LPCH Pediatric Intensive Care Unit.
GENERAL ANAESTHESIA M. Attia SVUH Feb.2007.
Anesthesia for Cesarean Section -Emergent C/S & General Anesthesia Department of Anesthesiology,NTUH R3 Chang-Fu Su.
Basic & Clinical Pharmacology Influence of liver impairment in the action of sodium thiopental.
Sedation, Analgesia and Paralytics in the ICU
Prof. Hanan Hagar Pharmacology Department. What student should know  Major body fluid compartments  Concept of compartments.  Apparent volume of distribution.
Drugs to Assist in Intubation Sara Park
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 4 Pharmacokinetics.
Inguinal Hernia of Premature Infants
Intravenous anesthetics. Toxicity of General Anesthesia.
Chapter 4 Pharmacokinetics Copyright © 2011 Delmar, Cengage Learning.
Pharmacokinetics of strong opioids Susan Addie Specialist palliative care pharmacist.
NEUROMUSCULAR JUNCTION BLOCKERS
1 Cholinergic Receptors Antagonists Section 2, lecture 3.
LOGO Sedation in the ICU Prof. Bahaa Ewees Ain Shams University.
11/22/20151 SKELETAL MUSCLE RELAXANTS. 211/22/2015 Classification on basis of site of action and mechanism of action A)PERIPHERALLY ACTING Neuromuscular.
Welcome! Webinar participants Please be sure your mic is on mute You can send messages in the chat pane Mute Cellphones 1.
INTRODUCTION CLINICAL PHARMACOKINETICS
INTRODUCTION OF TWO NEW ANESTHETIC AGENTS Dr.G.k.kumar.
Rapacuronium: 1. Is a depolarising muscle relaxant. 2. Is typically given in a dose of 1.5 mgs/kg. 3. Produces intubating conditions within 1 circulation.
Autonomic Nervous System 6-Anticholinergic Drugs
Local Anaesthesia and Vasoconstrictors
Endotracheal Intubation – Rapid Sequence Intubation
Neuromuscular Blocking Agents Dr. Ahmed Haki Ismael.
MCQ – I V INDUCTION AGENTS
Neuromuscular Blockers
Manufacturer: Merck FDA Approval Date: December 15, 2015
Rapid Sequence Intubation Drugs Ryan J. Fink, MD Raquel Bartz, MD Duke University Medical Center Dept. of Anesthesiology.
Anesthesia for Non-Obstetric Surgery Most common reasons for surgery: – Appendicitis – Cholecystitis – Trauma – Ovarian torsion.
Intubation in the ER ‘Chapter 2’
Skeletal muscle relaxants
MUSCLE RELAXANTS Dr Walid Zuabi FCA RCSI.
MUSCLE RELAXANTS Muscle relaxants are drugs that interrupt transmission of neural impulses at the neuromuscular junction.
MD., DA., DNB, MD (Acu), Dip. Diab. DCA, Dip. Software statistics,
NEUROMUSCULAR BLOCKING AGENTS
Pharmacodynamics: Pharmacological actions:
Rocuronium New drug authorized to administer by DHS. BUT is limited to use in a successfully intubated patient. Will only be used for patients being transferred.
School of Pharmacy, University of Nizwa
Anticholinesterase Drugs and Cholinergic Agonists
4th year Anaesthesia MBChB
Neuromuscular Blockade
Cholinergic Antagonist
Cholinergic Antagonist
Pharmacokinetics and Factors of Individual Variation
Pharmacology of Neuromuscular Blocking Drugs History And Clinical
Skeletal muscle relaxants
Non -depolarizing muscle relaxant
Skeletal muscle relaxants
Non -depolarizing muscle relaxant
Cholinesterase inhibitors
Cholinesterase inhibitors
Sedation and Analgesia in Acutely Ill Children
Developmental Pharmacology
Presentation transcript:

Rocuronium for rapid sequence induction Presenters: Dr. Said Nawaz. Dr.Reem Al-safar. Dr.Ahmed Al-sharif. Dr.Abdulla Al-harbi.

Rocuronium Bromide pharmacology Chemistry: Chemistry:  Monoquaternary Amino-steroid compound of Non-depolarizing neuromuscular blocking agents.  It was introduced 1995 CH 53 BrN 2 O 4 CH 53 BrN 2 O 4

 Presentation - Rocuronium is supplied as a sterile, isotonic solution that is clear. - Rocuronium is supplied as a sterile, isotonic solution that is clear. - pH of 4. - pH of 4.  Indications and usage - used to facilitate both rapid sequence and routine tracheal intubation. - used to facilitate both rapid sequence and routine tracheal intubation. - to provide skeletal muscle relaxation during surgery or mechanical ventilation. - to provide skeletal muscle relaxation during surgery or mechanical ventilation. - is also indicated as an adjunct in the intensive care unit (ICU) to facilitate intubation and mechanical ventilation - is also indicated as an adjunct in the intensive care unit (ICU) to facilitate intubation and mechanical ventilation

 Mechanism of action: It acts by competitve inhibition of α-subunit of nicotinic receptors at the motor end-plate. It acts by competitve inhibition of α-subunit of nicotinic receptors at the motor end-plate.  Onset of action: (Dose dependant) -ED95 0.3mg/kg -ED95 0.3mg/kg - Intubating dose 0.6mg/kg,maximal block 1.5min - Intubating dose 0.6mg/kg,maximal block 1.5min -Dose of mg/kg, maximal block sec. -Dose of mg/kg, maximal block sec. -In children : dose of 0.6mg/kg,maximal block 1min -In children : dose of 0.6mg/kg,maximal block 1min dose of 1.2mg/kg,maximal block 40 sec dose of 1.2mg/kg,maximal block 40 sec -Intrmuscular injection 1mg/kg for infants and 2mg/kg for children,maximal block 3-6 min. -Intrmuscular injection 1mg/kg for infants and 2mg/kg for children,maximal block 3-6 min.

 Duration of action: - Duration of action is determined by redistribution. - Duration of action is determined by redistribution. after 0.6mg/kg is 31 min after 0.6mg/kg is 31 min after mg/kg 58-67min after mg/kg 58-67min  Like other Non-DNMBA :it is highly ionized in water compound at physiological PH, VD is limited and can not cross lipid membrane barrier.  Metabolism and execration: -No metabolism. -No metabolism. -Eliminated primarily by liver and slightly by kidneys -Eliminated primarily by liver and slightly by kidneys - Elimination half life is 1-2h. - Elimination half life is 1-2h. -No active metabolites. -No active metabolites.

 Rocuronium in special situations

 Hepatic impairment  Onset time is unchanged  Duration of action is increased. (1.5 times longer)  Larger or repeat doses may have prolonged effect  Renal failure  Onset time is unchanged  Also, Duration of action is unchanged at the dose of 0.6mg/kg.

 Rocuronium and obesity  Same onset time compared to Non obese  Same Duration  Dose should be given according to Actual Body Weight.

 Rocuronium in Obstetric anesthesia  The umbilical venous plasma concentrations were 18% of maternal concentrations at delivery. Apgar score>7 in 5m.  Rocuronium can be used for rapid intubation during cesarian section if succinylcholine is contraindicated.(Koroglu et al.)

 Age and Rocuronium ( 0.6mg/kg )  Pediatrics (3 mos. - 1 yr):  excellent to good intubating conditions within 1 minute, with 41 minutes of clinical relaxation (median)  Pediatrics (1 yr - 12 yrs):  excellent to good intubating conditions within 1 minute, with 27 minutes of clinical relaxation (median)  Geriatric (  65 yrs):  excellent to good intubating conditions within 2.3 minutes, with 46 minutes of clinical relaxation (median)

The case of Rocuronium versus Succinylcholine for RSI

A comparison of Succinylcholine and Rocuronium for rapid sequence intubation of ED patients. Erik Laurin et al, california, AEMJ 2003  360 patients Sch  1.5 mg/kg  Relaxation 39±13 sec  Body movements 9.2±1.2  Vocal cords movements 9.0±1.5  Physician satisfaction +++  6 patients bradycardia with wide QRS  182 patients RCR  0.9 mg/kg  Relaxation 44±2.0 sec  Body movements 9.5±1.1  Vocal cords movements 9.2±1.2  Physician satisfaction  ++  None

Rocronium versus Succinylcholine: are they equally effective during RSI of aneasthesia Mazeruka A J., Chicago Anaesthesia and Analgesia 1998  30 children  Thiopentone 5mg/kg  SUX 1.5 mg/kg  30 children  Thiopentone 5mg/kg  RCR 1.2 mg/kg

What is the message?  Rocuronium can do every thing, what Succinylcholine does, with the equal efficiency, but more safely.

Limitations Not suitable for difficult intubation situation Not suitable for difficult intubation situation

Thank you